Mosquera Orgueira, AdriánPeleteiro Raíndo, AndrésCid López, MiguelAntelo Rodríguez, BeatrizDíaz Arias, José ÁngelFerreiro Ferro, RoiAlonso Vence, NataliaBendaña López, ÁngelesAbuín Blanco, AitorBao Pérez, LauraMelero Valentín, PaulaGonzález Pérez, Marta SoniaCerchione, ClaudioMartinelli, GiovanniMontesinos Fernández, PauPérez Encinas, Manuel MateoBello López, José Luis2025-07-182025-07-182021-02-16Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, et al. Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. Bertolini F, editor. PLOS ONE. 2021 Feb 16;16(2):e02470931932-6203https://hdl.handle.net/10347/42537Background FLT3 mutation is present in 25–30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously, a variable proportion of wild-type FLT3 patients also responded to these drugs. Methods We analyzed 6 different transcriptomic datasets of AML cases. Differential expression between mutated and wild-type FLT3 AMLs was performed with the Wilcoxon-rank sum test. Hierarchical clustering was used to identify FLT3-mutation like AMLs. Finally, enrichment in recurrent mutations was performed with the Fisher’s test. Results A FLT3 mutation-like gene expression pattern was identified among wild-type FLT3 AMLs. This pattern was highly enriched in NPM1 and DNMT3A mutants, and particularly in combined NPM1/DNMT3A mutants. Conclusions We identified a FLT3 mutation-like gene expression pattern in AML which was highly enriched in NPM1 and DNMT3A mutations. Future analysis about the predictive role of this biomarker among wild-type FLT3 patients treated with FLT3 inhibitors is envisaged.eng© 2021 Mosquera Orgueira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acute myeloid leukemiaFLT3 mutation-likejournal article10.1371/journal.pone.0247093open access